Delivery Order SPE2DB20D3104-SPE2DB22FV7V3

Award Date 6/29/22
Potential Completion Date 6/30/22
Potential Value $1.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Clindamycin PH 1% Gel, a prescription medication, with a ceiling value of $1,029.48 and a period of performance through May 19, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,132.42 firm fixed-price contract is for the delivery of 4567445128 CLINDAMYCIN 900 MG/50 ML-D5W 50ML, with a completion date of March 4, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a range of...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution and healthcare solutions provider. The $2,032.48 firm fixed-price contract is for the delivery of Clindamycin 600 mg/50 ml-D5W 50 ml, a medical product used in healthcare settings. The contract has an ultimate completion date of December 19, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $3,888.43 firm fixed-price contract is for the supply of Clindamycin Phosphate 1% gel, a topical antibiotic medication. This order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA's Troop Support Medical division, valued at $999,999,999 and running through November 2026. The IDC serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,048.20, is a Delivery Order for the supply of CLINDAMYCIN 600 MG/50 ML-D5W 50ML, a pharmaceutical product, with a performance period through December 31, 2024. AmerisourceBergen also holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a...
This federal contract award is for the delivery of Clindamycin PH 1% Gel in 30 gram quantities to the Defense Logistics Agency (DLA). The $2,326.73 firm-fixed-price contract was awarded to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. This is a delivery order issued under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which has a potential value of up to $999,999,999.00 and runs through November 2026. The...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,349.84 firm fixed-price delivery order (SPE2DB20D1109|SPE2DB24FP90Y) is for the supply of Clindamycin Phosphate 1% Gel, a topical antibiotic medication. The contract has an ultimate completion date of September 17, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation for the supply of Clindamycin 900 mg/50 ml-D5W 50 ml. The order has a ceiling value of $1,253.68 and a completion date of September 23, 2024. This is not a set-aside contract. AmerisourceBergen, a major pharmaceutical distributor, holds an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at up to $999,999,999 through December 2025 for delivering a wide range of...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp's Corporate Office division. The contract, valued at $1,226.44, is for the supply of Clindamycin 60ml medical products. The contract has a period of performance through September 11, 2024 and is a firm-fixed price contract. Amerisourcebergen is a major pharmaceutical and medical supply distributor that holds several Indefinite Delivery Contracts (IDCs) with federal...
This federal contract award, valued at $1,812.42, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of Clindamycin PH 1% Gel, a topical antibiotic medication, with a period of performance through October 2024. The contract is not designated under any set-aside program, indicating open competition. Amerisourcebergen Drug Corp is a for-profit...
  • SPE2DB20D3104
    Indefinite Delivery Contract
  • SPE2DB20D3104-SPE2DB22FV7V3
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,700.58, is for the delivery of 4557677832 (Clindamycin PH 1% Gel 30GM) and does not have a set-aside designation, indicating open competition.

AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 2/27/25, 11:34 AM